Key Highlights

  • Phase 2/3 randomized trial data for CTX-009 in biliary tract cancer due October 24 at ESMO.
  • Prior data showed median PFS of 4.7 months versus 2.6 months for paclitaxel alone.
  • Results reflected a 56% reduction in the risk of disease progression.
  • Compass shares trade near $2.05, with a market value of about $369 million.

Compass Therapeutics (NASDAQ: CMPX) is scheduled to present Phase 2/3 results from a randomized controlled trial of CTX-009, a DLL4 x VEGF-A bispecific antibody, in biliary tract cancer at the ESMO 2026 congress on October 24.

What Happened

The Phase 2/3 study, known as COMPANION-002, previously reported overall survival and progression-free survival data showing a statistically significant improvement versus paclitaxel alone, noted April 27, 2026.

The key secondary endpoint of median progression-free survival was 4.7 months for CTX-009 versus 2.6 months for paclitaxel, a 56% reduction in the risk of progression.

Separately, data noted April 1, 2025 showed a 17.1% overall response rate for CTX-009, including one complete response, compared with a 5.3% overall response rate for paclitaxel alone. Enrollment in the study completed August 6, 2024.

Market Reaction

Compass Therapeutics, a small-cap biotech with a market value of approximately $369 million, traded near $2.05 per share, down $0.05, or 2.38%, according to the disclosed pipeline database.

Outlook

Full Phase 2/3 results from the randomized controlled trial are scheduled to be presented at ESMO on October 24, 2026.

What is CTX-009 being studied for?

CTX-009, a DLL4 x VEGF-A bispecific antibody, is being studied in biliary tract cancer in the Phase 2/3 COMPANION-002 trial.

What did the COMPANION-002 trial show?

Data noted April 27, 2026 showed a median progression-free survival of 4.7 months versus 2.6 months for paclitaxel alone, a 56% reduction in progression risk.

When will full data be presented?

Phase 2/3 results from the randomized controlled trial are scheduled for presentation at ESMO on October 24, 2026.